- Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
-
Lee EY
- KMID: 2559010
- Diabetes Metab J.
- 2024 Sep;48(5):1005-1007.
- doi: 10.4093/dmj.2024.0417
-
- CITED
-
- Close
- SHARE
-
- Close
- Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
-
Park YH, Sohn M, Lim S
- KMID: 2559012
- Diabetes Metab J.
- 2024 Sep;48(5):1012-1013.
- doi: 10.4093/dmj.2024.0485
-
- CITED
-
- Close
- SHARE
-
- Close
- Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
-
Kim HS
- KMID: 2558998
- Diabetes Metab J.
- 2024 Sep;48(5):882-884.
- doi: 10.4093/dmj.2024.0479
-
- CITED
-
- Close
- SHARE
-
- Close
- Construction of Risk Prediction Model of Type 2 Diabetic Kidney Disease Based on Deep Learning (Diabetes Metab J 2024;48:771-9)
-
Seo BM, Choi JW
- KMID: 2559009
- Diabetes Metab J.
- 2024 Sep;48(5):1003-1004.
- doi: 10.4093/dmj.2024.0464
-
- CITED
-
- Close
- SHARE
-
- Close
- Construction of Risk Prediction Model of Type 2 Diabetic Kidney Disease Based on Deep Learning (Diabetes Metab J 2024;48:771-9)
-
Yun C, Tang F, Lou Q
- KMID: 2559011
- Diabetes Metab J.
- 2024 Sep;48(5):1008-1011.
- doi: 10.4093/dmj.2024.0490
-
- CITED
-
- Close
- SHARE
-
- Close
- Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
-
Jeon JY, Kim DJ
- KMID: 2558995
- Diabetes Metab J.
- 2024 Sep;48(5):837-846.
- doi: 10.4093/dmj.2024.0317
People with type 2 diabetes mellitus (T2DM) are at higher risk of developing cardiovascular disease, heart failure, chronic kidney disease, and premature death than people without diabetes. Therefore, treatment of... -
- CITED
-
- Close
- SHARE
-
- Close
- Systems Biology of Human Microbiome for the Prediction of Personal Glycaemic Response
-
Kirtipal N, Seo Y, Son J, Lee S
- KMID: 2558994
- Diabetes Metab J.
- 2024 Sep;48(5):821-836.
- doi: 10.4093/dmj.2024.0382
The human gut microbiota is increasingly recognized as a pivotal factor in diabetes management, playing a significant role in the body’s response to treatment. However, it is important to understand... -
- CITED
-
- Close
- SHARE
-
- Close
- Artificial Light at Night and Type 2 Diabetes Mellitus
-
Baek JH, Zhu Y, Jackson CL, Mark Park YM
- KMID: 2558996
- Diabetes Metab J.
- 2024 Sep;48(5):847-863.
- doi: 10.4093/dmj.2024.0237
The widespread and pervasive use of artificial light at night (ALAN) in our modern 24-hour society has emerged as a substantial disruptor of natural circadian rhythms, potentially leading to a... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Value of Plasma Endothelin-1 in Predicting Worse Outcomes in Patients with Prediabetes and Diabetes and Stable Coronary Artery Diseases
-
Yang C, Zhu CG, Guo YL, Wu NQ, Dong Q, Xu RX, Wu YJ, Qian J, Li JJ
- KMID: 2559008
- Diabetes Metab J.
- 2024 Sep;48(5):993-1002.
- doi: 10.4093/dmj.2023.0410
Background: Endothelin-1 (ET-1) is an endogenous vasoconstrictor implicated in coronary artery disease (CAD) and diabetes. This study aimed to determine the prognostic value of ET-1 in the patients with stable... -
- CITED
-
- Close
- SHARE
-
- Close
- Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
-
Heo JH, Han KA, Hong JH, Seo HA, Hong EG, Yu JM, Jung HS, Cha BS
- KMID: 2559003
- Diabetes Metab J.
- 2024 Sep;48(5):937-948.
- doi: 10.4093/dmj.2023.0314
Background: This study assessed the efficacy and safety of triple therapy with pioglitazone 15 mg add-on versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
-
Park JY, Lee J, Choi YH, Min KW, Han KA, Ahn KJ, Lim S, Kim YH, Ahn CW, Choi KM, Yoon KH, the Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators
- KMID: 2559001
- Diabetes Metab J.
- 2024 Sep;48(5):915-928.
- doi: 10.4093/dmj.2023.0259
Background: Guidelines for switching to triple combination therapy directly after monotherapy failure are limited. This study investigated the efficacy, long-term sustainability, and safety of either mono or dual add-on therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- A New Tool to Identify Pediatric Patients with Atypical Diabetes Associated with Gene Polymorphisms
-
Welsch S, Harvengt A, Gallo P, Martin M, Beckers D, Mouraux T, Seret N, Lebrethon MC, Helaers R, Brouillard P, Vikkula M, Lysy PA
- KMID: 2559004
- Diabetes Metab J.
- 2024 Sep;48(5):949-959.
- doi: 10.4093/dmj.2023.0166
Background: Recent diabetes subclassifications have improved the differentiation between patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus despite several overlapping features, yet without considering genetic forms... -
- CITED
-
- Close
- SHARE
-
- Close
- Glycemic Control and Retinal Microvascular Changes in Type 2 Diabetes Mellitus Patients without Clinical Retinopathy
-
Lee K, Lee GH, Lee SE, Yang JM, Bae K
- KMID: 2559007
- Diabetes Metab J.
- 2024 Sep;48(5):983-992.
- doi: 10.4093/dmj.2023.0149
Background: To investigate the association of glycemic control and retinal microvascular changes in patients with type 2 diabetes mellitus (T2DM) without diabetic retinopathy (DR). Methods: This retrospective, observational, cohort study included... -
- CITED
-
- Close
- SHARE
-
- Close
- Single-Cell Landscape and a Macrophage Subset Enhancing Brown Adipocyte Function in Diabetes
-
Gu J, Jin J, Ren X, Zhang X, Li J, Wang X, Zhang S, Yin X, Zhang Q, Wang Z
- KMID: 2558999
- Diabetes Metab J.
- 2024 Sep;48(5):885-900.
- doi: 10.4093/dmj.2023.0278
Background: Metabolic dysregulation is a hallmark of type 2 diabetes mellitus (T2DM), in which the abnormalities in brown adipose tissue (BAT) play important roles. However, the cellular composition and function... -
- CITED
-
- Close
- SHARE
-
- Close
- T-Cell Senescence in Human Metabolic Diseases
-
Nga HT, Nguyen TL, Yi HS
- KMID: 2558997
- Diabetes Metab J.
- 2024 Sep;48(5):864-881.
- doi: 10.4093/dmj.2024.0140
Immunosenescence denotes a state of dysregulated immune cell function characterized by a confluence of factors, including arrested cell cycle, telomere shortening, markers of cellular stress, mitochondrial dysfunction, loss of proteostasis,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus
-
Kang S, Ahn YB, Oh TK, Lee WY, Chun SW, Bae B, Dahaoui A, Jeong JS, Jung S, Jang HC
- KMID: 2559002
- Diabetes Metab J.
- 2024 Sep;48(5):929-936.
- doi: 10.4093/dmj.2023.0297
Background: This study investigated the real-world efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM), whose insulin treatment was switched to IDegAsp. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- DGAT2 Plays a Crucial Role to Control ESRRAPROX1 Transcriptional Network to Maintain Hepatic Mitochondrial Sustainability
-
Lee Y, Hwang Y, Kim M, Jeon H, Joo S, Fang S, Kim JW
- KMID: 2559000
- Diabetes Metab J.
- 2024 Sep;48(5):901-914.
- doi: 10.4093/dmj.2023.0368
Background: Diacylglycerol O-acyltransferase 2 (DGAT2) synthesizes triacylglycerol (TG) from diacylglycerol; therefore, DGAT2 is considered as a therapeutic target for steatosis. However, the consequence of inhibiting DGAT2 is not fully investigated... -
- CITED
-
- Close
- SHARE
-
- Close
- Biologically Informed Polygenic Scores for Brain Insulin Receptor Network Are Associated with Cardiometabolic Risk Markers and Diabetes in Women
-
Selenius JS, Silveira PP, Bonsdorff Mv, Lahti J, Koistinen H, Koistinen R, Seppälä M, Eriksson JG, Wasenius NS
- KMID: 2559005
- Diabetes Metab J.
- 2024 Sep;48(5):960-970.
- doi: 10.4093/dmj.2023.0039
Background: To investigate associations between variations in the co-expression-based brain insulin receptor polygenic score and cardiometabolic risk factors and diabetes mellitus. Methods: This cross-sectional study included 1,573 participants from the Helsinki... -
- CITED
-
- Close
- SHARE
-
- Close
- Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study
-
Chang Q, Zhang Y, Zhang T, Liu Z, Cao L, Zhang Q, Liu L, Sun S, Wang X, Zhou M, Jia Q, Song K, Ding Y, Zhao Y, Niu K, Xia Y
- KMID: 2559006
- Diabetes Metab J.
- 2024 Sep;48(5):971-982.
- doi: 10.4093/dmj.2023.0133
Background: The incidence density of metabolic dysfunction-associated fatty liver disease (MAFLD) and the effect of a healthy lifestyle on the risk of MAFLD remain unknown. We evaluated the prevalence and... -
- CITED
-
- Close
- SHARE
-
- Close
